Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
85 hedge funds and large institutions have $755M invested in Revance Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 11 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 28
4% more call options, than puts
Call options by funds: $728K | Put options by funds: $700K
4% more capital invested
Capital invested by funds: $727M → $755M (+$28.3M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
1% less funds holding
Funds holding: 86 → 85 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.74M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$3.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.17M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
-$11.6M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$2.36M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.1M |
| 4 |
JP Morgan Chase
New York
|
-$1.95M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.86M |
RVNC Hedge Fund Activity: Q3 2017 in Review
85 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q3 2017, worth a combined $755M — up 3.9% from $727M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RVNC and 10 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 32 added.
The largest buyer was Wellington Management Group, adding an estimated $9.74M. The largest seller was PointState Capital, exiting entirely with an estimated $11.6M sold.
- 85 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q3 2017, down from 86 in Q2 2017.
- Funds reported $755M of Revance Therapeutics, Inc. stock for Q3 2017, up 3.9% quarter-over-quarter.
- 10 funds opened new Revance Therapeutics, Inc. positions in Q3 2017 and 11 closed out, a net change of -1 holder.
- The largest Revance Therapeutics, Inc. buyer in Q3 2017 was Wellington Management Group, an estimated $9.74M added.
- The largest Revance Therapeutics, Inc. seller in Q3 2017 was PointState Capital, an estimated $11.6M sold.
Based on aggregated 13F filings for Q3 2017.